| abstract |
The present invention relates to a method for providing information on chronic myelogenous leukemia using CobII1 (Cordon-bleu protein-like 1), more specifically, diagnosis of conversion from chronic myelogenous leukemia to acute phase, conversion from chronic myelogenous leukemia to acute phase Prognosis, resistance to various therapeutic agents for chronic myelogenous leukemia including tyrosine kinase inhibitor, etc., and can be used to diagnose patients who have not been predicted and diagnosed by the conventional BCR-ABL1 gene measurement Therefore, it is expected to be useful for the prediction and diagnosis of various prognosis such as progression, recurrence, drug resistance, and chronic myelogenous leukemia. In addition, the use of an oligonucleotide that specifically binds to the CobII1 mRNA of the present invention inhibits the expression of CobII1 protein, thereby effectively inhibiting cell proliferation and resistance to drugs, and is useful for the treatment of chronic myelogenous leukemia and for the acute phase of chronic myelogenous leukemia It is expected that the conversion will be effectively suppressed. |